Growing Adoption Of Recombinant Vaccines Is Fueling Growth Of Hepatitis Vaccine Market

The global Hepatitis Vaccine Market is estimated to be valued at US$ 8.39 Bn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Hepatitis vaccines help prevent liver infections caused by hepatitis A, B, and C viruses. Recombinant vaccines are safer and have fewer side effects than older hepatitis vaccines produced from infected human/animal blood or plasma. They provide effective protection against hepatitis and help reduce the risks of developing chronic hepatitis and liver diseases like cirrhosis or liver cancer.

Hepatitis vaccines offer immunization against hepatitis viruses by active immunization which helps develop adaptive immunity and produce memory cells that will respond quickly if exposed to these viruses in future. There are vaccines available for hepatitis A, B, and E which help prevent new infections, specifically among high-risk groups like healthcare workers, people with malignant conditions, international travelers, and military personnel who have high chances of exposure to these viruses. The growing awareness about advantages of immunization is fueling adoption of hepatitis vaccines globally.

Market key trends:
One of the key trends fueling the hepatitis vaccine market growth is the increasing demand for recombinant vaccines. Recombinant vaccines use sophisticated genetic engineering techniques to produce immunogenic proteins of hepatitis viruses which are safer and have fewer side effects compared to plasma-derived vaccines produced from infected human blood. They offer long-lasting immunity, are more stable at variable temperatures, and eliminate the risk of transmitting other infectious agents. The safety advantages of recombinant vaccines over plasma-derived vaccines have led to their wider acceptance globally and driven the market growth. Additionally, rapid urbanization and globalization have increased the risk of spreading Hepatitis infections worldwide, thereby boosting the adoption of hepatitis vaccines programs implemented by governments and international organizations.
Segment Analysis
The global hepatitis vaccine market is segmented by disease type, vaccine type, end-user, and region. Based on disease type, the hepatitis A segment held the largest market share in 2023 owing to the high efficiency and availability of hep A vaccines. Hepatitis A vaccines provide lifelong immunity against the hepatitis A virus with a single dose booster. Based on vaccine type, the inactivated vaccines segment accounted for the maximum revenue share in 2023 due to the high prevalence of inactivated hepatitis A and B vaccines. Based on end-user, the hospitals & clinics segment dominated the market in 2023 as hospitals offer more advanced healthcare facilities including vaccination.

Key Takeaways
Global Hepatitis Vaccine Market Size is expected to witness high growth, exhibiting CAGR of 5.7% over the forecast period, due to increasing prevalence of hepatitis and rising awareness regarding vaccinations.

Regional analysis
North America captured the largest revenue share in the hepatitis vaccine market in 2023 owing to the widespread adoption of advanced vaccination programs and established healthcare infrastructure in the region. Asia Pacific is projected to witness the fastest growth during the forecast period owing to rising healthcare spending, presence of developing countries, and growing epidemic of hepatitis infections in countries like India and China.

Key players
Key players operating in the hepatitis vaccine market are Nestle S.A, Mars, Incorporated, Royal Canin SAS, Hill’s Pet Nutrition Inc., Unicharm Corporation, Heristo AG, Yantai China Pet Foods Co., Ltd., and Central Proteina Prima Tbk, among others. Nestle S.A dominated the market in 2023 due to its diverse portfolio of hepatitis vaccines for hepatitis A, B, and other viruses. Mars, Incorporated has a strong brand presence worldwide and offers cost-effective vaccine options for developing regions.